We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Gas Analyzer Enhances Diagnostic Testing

By LabMedica International staff writers
Posted on 01 Nov 2011
The latest cartridge-based analyzer for critical care testing has been introduced offering new features designed for ease-of-use at the point of care (POC). More...


The blood gas analyzer will aid clinicians who are increasingly relying on critical-care tests, such as blood gases, to deliver fast, accurate results to help guide treatment decisions.

The RAPIDPoint 500 analyzer offers a comprehensive menu of critical-care tests for pH and blood gases, electrolytes, glucose and lactate1 and full carbon monoxide (CO)-oximetry, including neonatal total bilirubin and total hemoglobin, all from a single, whole-blood sample. The results are obtained in approximately 60 seconds. Additionally, the measurement cartridges last up to 28 days and contain a full complement of tests, which reduces downtime.

Equipped with fully automated calibration and Quality Control (QC), the RAPIDPoint 500 system (Siemens Healthcare Diagnostics; Erlangen, Germany) is also designed to help POC professionals satisfy organizational and regulatory compliance requirements. The self-contained Automatic Quality Control (AQC) cartridges operate without manual intervention, helping reduce POC staff’s administrative tasks. An integrated bar code reader conveniently located on the front of the system offers a wide scanning area to accommodate patient and operator identification to ensure overall data entry integrity.

Hilda Crockett, the business manager for Point of Care at Siemens Healthcare Diagnostics, said, “The RAPIDPoint 500 system is designed to satisfy the unique demands of testing at the point of care. In addition to being easy-to-use, the analyzer leverages proven and reliable cartridge-based technologies to deliver fast, accurate, laboratory-quality results, helping clinicians feel confident in making critical decisions that impact patient lives.”

Related Links:

Siemens Healthcare Diagnostics




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.